In a patient taking gliclazide 120 mg with a hemoglobin A1c of 10 %, should the gliclazide dose be reduced by half or discontinued when initiating basal insulin therapy?

Continue Gliclazide at Full Dose When Starting Basal Insulin

In a patient with an A1C of 10% on gliclazide 120mg, you should continue the gliclazide at its current dose when initiating basal insulin, rather than reducing or stopping it. The most recent ADA guidelines explicitly recommend maintaining glucose-lowering agents when starting insulin for their ongoing glycemic and metabolic benefits 1, 2.

Rationale for Continuing Gliclazide

The 2025 ADA Standards of Care state that "glucose-lowering agents may be continued upon initiation of insulin therapy (unless contraindicated or not tolerated) for ongoing glycemic and metabolic benefits" 1. This represents the current standard approach to insulin initiation in type 2 diabetes.

When to Reduce or Stop Sulfonylureas

The guidelines make a critical distinction: you should only reassess the dose of sulfonylureas when they pose a higher hypoglycemia risk 2. Specifically, the ADA recommends to "reassess the need for and/or dose of glucose-lowering agents with higher hypoglycemia risk (i.e., sulfonylureas and meglitinides)" when starting insulin 2.

The key question is: Does your patient have significant hypoglycemia risk factors?

Decision Algorithm

Continue gliclazide 120mg if:

• No history of hypoglycemia
• Patient is younger with good awareness
• No significant renal impairment
• Patient can monitor glucose regularly

Consider reducing gliclazide dose by 50% if:

• History of hypoglycemia episodes
• Elderly or frail patient
• Impaired hypoglycemia awareness
• Renal impairment present
• Poor access to glucose monitoring

Stop gliclazide if:

• Severe renal impairment (contraindication)
• Recurrent severe hypoglycemia
• Patient cannot recognize or manage hypoglycemia

Practical Implementation

When initiating basal insulin in your patient:

1. Start basal insulin at 10 units daily or 0.1-0.2 units/kg/day 1
2. Keep gliclazide at 120mg (unless specific risk factors above)
3. Titrate insulin by 2 units every 3 days to reach fasting glucose goal 1
4. Monitor closely for hypoglycemia during the first 2-4 weeks
5. If hypoglycemia occurs without clear cause, reduce insulin dose by 10-20% first 1, then consider reducing gliclazide if hypoglycemia persists

Important Caveats

The A1C of 10% indicates severe hyperglycemia, which actually reduces immediate hypoglycemia risk when starting insulin. At this level of hyperglycemia, the additive effect of gliclazide plus basal insulin is beneficial for achieving glycemic control more rapidly 3.

Gliclazide-MR has demonstrated comparable efficacy to basal insulin in patients with A1C >10%, with both achieving significant reductions in glycemic indices 3. The combination provides complementary mechanisms: basal insulin addresses fasting hyperglycemia while gliclazide provides additional postprandial coverage.

Do not abruptly discontinue gliclazide as this risks rebound hyperglycemia 4. The goal is smooth glycemic control, not creating additional glucose variability.

Monitoring Strategy

• Check fasting glucose daily for insulin titration
• Monitor for hypoglycemia symptoms, especially 3-4 hours post-meals (when gliclazide peaks)
• Reassess at 2 weeks: if hypoglycemia occurs, reduce gliclazide dose at that point
• Once fasting glucose is controlled, evaluate postprandial glucose to determine if gliclazide dose is appropriate

The evidence strongly supports maintaining oral agents when starting insulin unless specific contraindications exist, with dose reduction reserved for those at higher hypoglycemia risk rather than being a routine practice.